TIDMSENS
RNS Number : 6066Q
Sensyne Health PLC
01 March 2021
Board changes
Oxford, U.K. 01 March 2021: Sensyne Health plc (LSE: SENS)
("Sensyne" or the "Company" or the "Group"), the British Clinical
AI technology company, is today pleased to announce additions to
its Board.
Richard Pye has been appointed as Chief Financial Officer and
Executive Director. Richard was previously Sensyne's Chief
Investment Officer. Michael Norris, Sensyne's former Interim Chief
Financial Officer, and Geoff Race will join the Sensyne Board as
Non-Executive Directors. These appointments became effective on 26
February 2021.
Sir Bruce Keogh, Chairman of Sensyne Health, said:
"I am delighted to welcome Richard, Geoff and Michael to the
Board of Sensyne. I would like to thank Michael for his excellent
service as Interim CFO and I am delighted he has agreed to stay
with the business as a Non-Executive Director. These senior
appointments, combined with our strong team, will help us boost
commercial momentum and accelerate the scaling of the business
internationally."
Dr. Richard Pye
Dr. Richard Pye has over 15 years' experience in corporate
finance and investor relations in the public market life science
sector. Prior to joining Sensyne, Richard was at Summit
Therapeutics plc, an AIM and Nasdaq-listed biopharmaceutical
company, where he held a number of leadership roles including most
recently the position of Vice President of Corporate Affairs and
Investor Relations. At Summit, he was involved in a wide range of
corporate activities including financial reporting, cross border
capital raises, corporate development and strategy, investor
communications and corporate governance. Richard holds a PhD in
organic chemistry and was a Post-Doctoral Research Associate at the
University of Oxford prior to moving into the life sciences
industry.
Michael Norris
Michael Norris has served as Sensyne's Interim CFO since March
2020 and has more than 20 years of experience working with public
and private companies in the technology and life sciences sectors.
Michael is currently also Director and CFO of Beckley Psytech Ltd,
a company developing a pipeline of psychedelic compounds into
licensed pharmaceutical medicines. He has a wealth of CFO and
Interim CFO experience having served in those roles for several
companies in the UK and US. Michael is a Fellow of the Chartered
Institute of Management Accountants.
Geoff Race
Geoff Race is the co-founder, EVP, CFO, and CBO of Nasdaq listed
biopharmaceutical company Minerva Neurosciences Inc. He has more
than 20 years of experience as CEO and CFO in the life science
industry, including roles at Funxional Therapeutics Ltd,
PanGenetics BV and CareX SA. Geoff is also a Non-Executive Director
at Nasdaq listed F-star Therapeutics Inc. and Chairman and
co-founder of London based consumer behaviour data providers, Huq
Industries Ltd. Geoff received an MBA from Durham University
Business School, UK, and is a Fellow of the Chartered Institute of
Management Accountants.
Regulatory Disclosures
The following information is disclosed pursuant to Schedule Two,
paragraph (g) of the AIM Rules for Companies:
Dr. Richard Joseph Pye (age 44)
There is no further information required to be disclosed
pursuant to Schedule Two paragraph (g) of the AIM Rules in respect
of Mr Pye.
Michael John Norris (age 56)
Current Directorships or Partnerships:
-- Beckley Psytech Ltd
-- Rivertime Corporate Finance Ltd
-- Norris Biomedical Services Ltd
-- Secret Saviours Ltd
-- Rapid Rhythm Ltd
Directorships or partnerships held within the past 5 years:
-- Sporting Club Leigh Ltd
-- MedeTrax Ltd
-- Biosensors Ltd
-- Alchemy Pharmatech Ltd
-- TTS Pharma Ltd
-- Albert Medical Devices Ltd
-- Michael Norris Consultancy Limited
Michael Norris is an experienced financial consultant and
earlier in his career he was involved in a number of financial
turnaround situations. He was a director of i3-Group Limited from
2011 until 2013, less than 12 months prior to the company entering
into voluntary liquidation in 2014 with no shortfall to creditors.
The company was dissolved and subsequently restored. Michael has no
association with the similarly named i3 Group Limited. Michael was
CEO of Micap plc (and its wholly owned subsidiaries Applied
Analysis Limited, Micap Ingredients Limited and F.S.M. Technologies
Limited) which went into administration in November 2008 with a
shortfall to creditors of approximately GBP1.2 million. Michael was
a director of Rivertime Restaurants Limited within the 12 months
preceding its administration and GBP65,000 shortfall to
creditors.
Michael Norris holds 27,777 shares in the Company, representing
0.02% of the issued share capital.
There is no further information required to be disclosed
pursuant to Schedule Two paragraph (g) of the AIM Rules in respect
of Mr Norris.
Geoffrey Robin Race (age 60):
Current Directorships or Partnerships:
-- Minerva Neurosciences Inc (CFO & CBO)
-- F-Star Therapeutics Inc
-- F-Star Biotechnologische Forschungs- und Entwicklungsges.m.b.H
-- Huq Industries Ltd
Directorships or partnerships held within the past 5 years:
-- F-Star Biotechnology Ltd
Geoff Race was a director of All Wheel Drive Limited, a company
under common ownership with Artix Limited, when it went into
receivership in 1992. Records indicate there may have been a
shortfall to creditors.
There is no further information required to be disclosed
pursuant to Schedule Two paragraph (g) of the AIM Rules in respect
of Mr Race.
-ENDS-
For more information please contact:
Sensyne Health ( www.sensynehealth.com +44 (0) 330 058
) 1845
Lord (Paul) Drayson PhD FREng, Chief Executive
Officer
Dr Richard Pye, Chief Financial Officer
Peel Hunt LLP (Nominated Adviser and Joint + 44 (0) 20 7418
Broker) 8900
Dr Christopher Golden
James Steel
Oliver Jackson
+ 44 (0) 20 3100
Liberum (Joint Broker) 2000
Bidhi Bhoma
Euan Brown
+44 (0) 20 3709
Consilium Strategic Communications 5700
Mary-Jane Elliott
Sukaina Virji
Davide Salvi
CSCS ensynehealth@consilium-comms.com
About Sensyne Health www.sensynehealth.com .
Sensyne Health plc is a clinical AI company that works in
partnership with the NHS to improve patient care and accelerate the
discovery and development of new medicines. This work uses data
provided by patients and collected by the NHS as part of their care
and support. Sensyne Health is listed on the AIM Market of the
London Stock Exchange (SENS.L).
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOADKFBPDBKBFBB
(END) Dow Jones Newswires
March 01, 2021 02:00 ET (07:00 GMT)
Sensyne Health (LSE:SENS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sensyne Health (LSE:SENS)
Historical Stock Chart
From Apr 2023 to Apr 2024
